Novo Nordisk A/S (NONOF)
Novo Nordisk A/S operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Bagsvaerd, CR, DK. The stock last traded at $38.66, up 0.68% on the session, giving a market capitalisation of $171.67B. On trailing twelve-month figures it carries a trailing P/E of 9.65, a net margin of 35.3%. Its beta of 0.35 implies it has historically moved less than the broad market.
Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Its extensive operations are primarily structured into two distinct divisions: Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment offers comprehensive solutions, encompassing various insulin preparations, GLP-1 receptor agonists along with their delivery systems, oral antidiabetic medications, treatments for weight management, and therapies addressing other chronic health conditions. Meanwhile, the Biopharmaceuticals division is focused on specialized treatments for hemophilia, growth hormone disorders, and hormone replacement therapy. The company actively engages in strategic collaborations, notably including an agreement with Gilead Sciences, Inc. Furthermore, Novo Nordisk A/S is engaged in a research partnership with Lumen Bioscience, Inc., aiming to explore innovative methods for administering oral biologics for the management of cardiometabolic diseases. Established in 1923, the company's main corporate offices are located in Bagsvaerd, Denmark.
Novo Nordisk A/S is most often compared with the following Healthcare names: